Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $25 Million Financing for EyeYon Medical’s EndoArt® Clinical Trials Across Three Continents
March 15, 2021 13:05 ET | Source: Quark Venture LP Quark Venture LP Vancouver, British Columbia, CANADA
VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) Quark Venture LP (Quark) and GF Securities participated in the $25 million financing of EyeYon Medical, to advance its EndoArt
® clinical trials. This investment, made through the Global Health Sciences (GHS) fund, was led by a global ophthalmology industry leader and CRCP alongside new and existing shareholders BPC, Diamond BioFund, Rimonci, Pontifax and Triventures.
Quark Venture’s investment in EyeYon Medical will enable the corneal healing solutions provider to accelerate its EndoArt